Spyre Therapeutics
Spyre Therapeutics reported revenue of $0 million in fiscal 2025.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Spyre Therapeutics does
Spyre Therapeutics is a drug developer. It does not sell any medicine yet. It is working on antibody drugs for inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis, and for rheumatic diseases such as rheumatoid arthritis.
Its pipeline has three antibody candidates, each aimed at a different target in the immune system: one called alpha-4 beta-7, one called TL1A and one called IL-23. The company changed each antibody so that it stays in the body longer, which could allow dosing by injection only every few months. It plans to test them alone and in pairs, because it believes a combined treatment could work better than one drug.
It also plans to test its TL1A antibody in other diseases, starting with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. Spyre has never earned revenue from selling a product. It pays for its work with money raised from investors, and says it will need to raise more.
Its biggest risks, as it describes them
- Needing to raise more money, which could dilute shareholders, and having no revenue from product sales.
- Depending heavily on the success of a few antibody programs and their clinical trials.
- Competition from other companies working on the same diseases and drug targets.
- Early or interim trial results that may change as more patient data comes in.
- Difficulty enrolling patients in trials, which could delay its development work.
Income statement
Spyre Therapeutics lost money in fiscal 2025: a net loss of $155 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 93 | 56 | 339 | 603 | 756 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 4.9x | 4.2x | 10.7x | 11.3x | 13.2x |
| Quick ratio | 4.9x | 4.2x | 10.7x | 11.3x | 13.2x |
Cash flow
Projections
Project Spyre Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Spyre Therapeutics shares on the open market, and 7 insiders sold $435.7 million, $34.7 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Scott L BurrowsChief Financial Officer | Sold plan | 18,232 | $89.35 | $1.6 million | Form 4 |
| Sep 2, 2026 | Heidy King-JonesSee Remarks | Sold plan | 400 | $90.00 | $36,000 | Form 4 |
| Sep 1, 2026 | Heidy King-JonesSee Remarks | Sold plan | 27,999 | $87.31 | $2.4 million | Form 4 |
| Sep 1, 2026 | Cameron TurtleChief Executive Officer, Director | Sold plan | 15,000 | $87.29 | $1.3 million | Form 4 |
| Sep 1, 2026 | Scott L BurrowsChief Financial Officer | Sold plan | 7,500 | $87.31 | $654,792 | Form 4 |
| Aug 7, 2026 | Jeffrey W. AlbersDirector | Sold plan | 23,000 | $104.53 | $2.4 million | Form 4 |
| Aug 3, 2026 | Cameron TurtleChief Executive Officer, Director | Sold plan | 15,000 | $95.51 | $1.4 million | Form 4 |
| Aug 3, 2026 | Scott L BurrowsChief Financial Officer | Sold plan | 7,500 | $95.57 | $716,771 | Form 4 |
| Jul 1, 2026 | Cameron TurtleChief Executive Officer, Director | Sold plan | 15,000 | $87.69 | $1.3 million | Form 4 |
| Jul 1, 2026 | Sheldon SloanChief Medical Officer | Sold plan | 8,334 | $87.70 | $730,896 | Form 4 |
| Jul 1, 2026 | Scott L BurrowsChief Financial Officer | Sold plan | 7,500 | $87.74 | $658,040 | Form 4 |
| Jun 25, 2026 | Scott L BurrowsChief Financial Officer | Sold | 15,000 | $87.13 | $1.3 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −11,338.5% | — | — |
| Altman Z'' | −3.48 | 4.46 | 11.54 |
| Accruals ratio | −115.7% | −10.7% | 2.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Fail | — | — |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Fail | Fail |
| F-score | — | — | — |
Compare
Put Spyre Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Spyre Therapeutics | FY25 | — | — | — | — | — | — | |
| Acadia Pharmaceuticals | FY25 | 11.9% | 9.8% | 9.8% | — | — | — | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
| Agios Pharmaceuticals | FY25 | 48.0% | −873.9% | −698.3% | — | — | — | Compare |
| Alkermes | FY25 | −5.2% | 17.2% | 32.5% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 5 | 5 | 4 | 0 | 0 | 19 | 2 | 1 | 0 | 0 |
| Revenue growth | — | 12.5% | −25.3% | −100.0% | — | — | −87.6% | −62.0% | −100.0% | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 18 | 23 | 37 | 65 | 60 | 57 | 59 | 90 | 163 | 172 |
| Operating income | −22 | −28 | −46 | −80 | −82 | −66 | −85 | −242 | −209 | −210 |
| Net income | −22 | −27 | −44 | −78 | −81 | −66 | −84 | −339 | −208 | −155 |
| Diluted EPS (US$) | −55.50 | −45.00 | −53.25 | −61.25 | −38.00 | −25.02 | −24.86 | 13.76 | — | — |
| Diluted shares (millions) | 0 | 1 | 1 | 1 | 2 | 3 | 3 | 7 | — | — |
| Cash flow | ||||||||||
| Cash from operations | −19 | −25 | −32 | −66 | −76 | −54 | −80 | −100 | −157 | −169 |
| Capital expenditure | 0 | 1 | 0 | 2 | 4 | 1 | 0 | 0 | 0 | — |
| Free cash flow | −19 | −25 | −33 | −67 | −80 | −54 | −80 | −100 | −157 | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 1 | 2 | 4 | 5 | 6 | 8 | 7 | 26 | 45 | 38 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 64 | 50 | 74 | 72 | 146 | 93 | 56 | 339 | 603 | 756 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 67 | 56 | 78 | 83 | 162 | 110 | 71 | 342 | 608 | 778 |
| Total liabilities | 4 | 6 | 10 | 23 | 22 | 26 | 21 | 73 | 91 | 62 |
| Shareholders' equity | 63 | 50 | 67 | 60 | 140 | 84 | 50 | 184 | 518 | 715 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −473.3% | −531.7% | −1,169.3% | — | — | −350.3% | −3,640.2% | −27,348.0% | — | — |
| Net margin | −468.8% | −523.3% | −1,140.6% | — | — | −351.1% | −3,598.8% | −38,238.2% | — | — |
| Free cash flow margin | −411.7% | −484.8% | −838.9% | — | — | −289.7% | −3,442.8% | −11,276.5% | — | — |
| Rule of 40 (growth + FCF margin) | — | −472.3% | −864.2% | — | — | — | −3,530.3% | −11,338.5% | — | — |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −106.5% | −48.1% | −75.3% | −122.7% | −80.9% | −58.8% | −124.9% | −289.2% | −59.3% | −25.2% |
| Return on assets | −41.0% | −44.2% | −66.3% | −97.3% | −66.1% | −48.5% | −92.6% | −164.1% | −43.8% | −22.4% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |